A review exploring the translational perspective of artificial intelligence in drug discovery and formulation development.
Publication Year:
2026
PubMed ID:
41653969
Funding Grants:
Public Summary:
Developing a new medicine is historically a grueling process, often taking over a decade and costing billions of dollars. To fix this, pharmaceutical companies are using artificial intelligence (AI) to fundamentally transform every step of drug development, cutting total costs by up to 40% and slashing development timelines in half. Instead of years of manual lab work, AI can screen billions of chemical compounds in months, accurately predict toxic side effects to eliminate up to 40% of animal testing, and use "digital twin" simulations to safely reduce the number of human patients needed for clinical trials. While hurdles like data quality, algorithmic bias, and regulatory approvals still need to be addressed, this technology is successfully shifting medicine away from slow, trial-and-error experimentation and toward a faster, more predictable future for lifesaving treatments.
Scientific Abstract:
The drug development pipeline remains extraordinarily complex, costly, and time-intensive, typically requiring 10-15years and $2-3 billion per approved drug. This review presents a translational perspective on how artificial intelligence (AI) and machine learning (ML) are renovating pharmaceutical R&D across the entire value chain while maintaining rigorous safety and efficacy standards. In drug discovery, deep learning platforms enable virtual screening of billion-compounds, reducing target identification from years to months while improving hit rates by 30-50%. Preclinical development benefits from AI-powered toxicity prediction, potentially eliminating 40% of animal testing through accurate in silico models. Clinical trials are optimized through digital twin technology, reducing patient cohorts by 25-30% without compromising statistical power. Post-marketing surveillance is accelerated 100-fold through AI-driven real-world evidence analysis. Across the development lifecycle, AI delivers 30-60% time savings and 25-40% cost reductions while increasing success rates through enhanced predictive capabilities. Formulation development benefits from ML algorithms that optimize drug compositions and stability, reducing trial-and-error experimentation. However, challenges persist in data quality, algorithmic bias, and regulatory acceptance of AI-derived evidence. This review provides a balanced perspective on AI's transformative potential in drug discovery and various formulation developments, along with its limitations, offering a roadmap for successful implementation in pharmaceutical R&D.